Share on LinkedInShare on LinkedIn

ARTICLE · 25 OCTOBER 2014

Dr. Reddy’s Laboratories Settles On Eve Of Trial – Agrees To Cooperate With Plaintiffs

Much has happened since our last post on the Nexium "pay for delay" class action lawsuit. Jury selection began in the District of Massachusetts on Monday, October 20, 2014.

United StatesAntitrust/Competition Law

Much has happened since our last post on the Nexium "pay for delay" class action lawsuit. Jury selection began in the District of Massachusetts on Monday, October 20, 2014. The day prior, one of the generic drug makers, Dr. Reddy's Laboratories ("DRL"), settled with the plaintiffs and agreed to cooperate in plaintiffs' case against AstraZeneca, Teva Pharmaceutical Industries, and Ranbaxy Inc.

Plaintiffs' primary claim is that AstraZeneca made an Actavis-type large payment to Ranbaxy, Teva, and DRL to keep their generic drugs off the market. Thus, plaintiffs argue, they were forced to pay higher prices for Nexium.

Prior to the settlement, Judge Young made an evidentiary ruling that limits plaintiffs' plans for their case-in-chief. He quashed a subpoena from the plaintiffs seeking to require Covington & Burling LLP partner, Timothy Hester, to give live trial testimony. The plaintiffs sought Mr. Hester's testimony because allegedly he "was at the center of a small

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from